{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:23:34Z","timestamp":1768001014978,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.clml.2015.05.007","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T23:11:49Z","timestamp":1433632309000},"page":"519-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed\/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial"],"prefix":"10.1016","volume":"15","author":[{"given":"Katja","family":"Weisel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Belch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Schey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Sternas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Amatya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig J.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.05.007_bib1","unstructured":"Durie BGM. Concise review of the disease and treatment options: multiple myeloma cancer of the bone marrow. International Myeloma Foundation 2011\/2012."},{"key":"10.1016\/j.clml.2015.05.007_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2015.05.007_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur\u00a0J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pon.1710","article-title":"Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners","volume":"20","author":"Molassiotis","year":"2011","journal-title":"Psychooncology"},{"key":"10.1016\/j.clml.2015.05.007_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2015.05.007_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.05.007_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00259-005-0004-3","article-title":"Role of 18F-FDG PET\/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results","volume":"33","author":"Nanni","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2015.05.007_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.blre.2011.03.005","article-title":"Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?","volume":"25","author":"Palumbo","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2015.05.007_bib11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.05.007_bib12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-10-1925","article-title":"Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival","volume":"17","author":"Palumbo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2015.05.007_bib13","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","article-title":"Recent major improvement in long-term survival of younger patients with multiple myeloma","volume":"111","author":"Brenner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.05.007_bib14","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.05.007_bib15","unstructured":"Verelst S, Karim-Kos H, Blommestein H, et\u00a0al. Are we making progress? Survival in plasma cell malignancies in the era of novel treatments a population based study of 17.790 patients in The Netherlands. Proceedings of the 17th Congress of the\u00a0European Hematology Association (EHA), Amsterdam, The Netherlands. Haematologica 2012; 97:242 (abstract 0592)."},{"key":"10.1016\/j.clml.2015.05.007_bib16","doi-asserted-by":"crossref","unstructured":"Verelst SGR, Blommestein HM, Karim-Kos HE, et\u00a0al. Trends in incidence and survival of multiple myeloma in the Netherlands in the last two decades. Results from a national population based study. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA. Blood 2011; 118:abstract\u00a05071.","DOI":"10.1182\/blood.V118.21.5071.5071"},{"key":"10.1016\/j.clml.2015.05.007_bib17","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.05.007_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.05.007_bib19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1600-0609.2009.01303.x","article-title":"Health-related quality of life assessment in randomized controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations","volume":"83","author":"Kvam","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib20","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.05.007_bib21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/2040620713480155","article-title":"Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist","volume":"4","author":"McCurdy","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2015.05.007_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2015.05.007_bib23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.05.007_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1475-6773.2005.0k375.x","article-title":"Commentary\u2014goodbye M(C)ID! Hello MID, where do you come from?","volume":"40","author":"Schunemann","year":"2005","journal-title":"Health Serv Res"},{"key":"10.1016\/j.clml.2015.05.007_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-8-79","article-title":"Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma","volume":"8","author":"Kvam","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2015.05.007_bib26","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/ejh.12012","article-title":"What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools","volume":"89","author":"Osborne","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1385\/MO:18:1:65","article-title":"Health-related quality of life in multiple\u00a0myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support","volume":"18","author":"Gulbrandsen","year":"2001","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2015.05.007_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2004.00346.x","article-title":"Health related quality of life in patients with multiple myeloma undergoing a double transplantation","volume":"74","author":"Uyl-de Groot","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group","volume":"92","author":"Wisloff","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2141.1997.222667.x","article-title":"Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group","volume":"97","author":"Wisloff","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2015.05.007_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","article-title":"Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life","volume":"104","author":"Stead","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib34","unstructured":"EORTC Quality of Life questionnaires. Available at: http:\/\/groups.eortc.be\/qol\/. Accessed: July\u00a02013."},{"key":"10.1016\/j.clml.2015.05.007_bib35","unstructured":"Cheung K, Oemar M, Oppe M, et\u00a0al. On behalf of the EuroQol Group. EQ-5D User Guide. Basic information on how to use EQ-5D. version 2.0, March 2009. Available at: http:\/\/www.euroqol.org. Accessed: January\u00a02014."},{"key":"10.1016\/j.clml.2015.05.007_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-12-35","article-title":"Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma","volume":"12","author":"Proskorovsky","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clml.2015.05.007_bib37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2015.05.007_bib38","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2015.05.007_bib39","doi-asserted-by":"crossref","unstructured":"Song KW, Dimopoulos MA, Weisel K, et\u00a0al. Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) improves health-related quality of life (HRQoL) vs high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM) patients enrolled in MM-003 phase 3 randomized trial. Proceedings of the 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA. Blood 2013; 122:abstract\u00a02939.","DOI":"10.1182\/blood.V122.21.2939.2939"},{"key":"10.1016\/j.clml.2015.05.007_bib40","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1093\/annonc\/mds175","article-title":"Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2015.05.007_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","article-title":"Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences","volume":"72","author":"Gulbrandsen","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib42","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.05.007_bib43","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.05.007_bib44","unstructured":"Pomalyst\u00ae (pomalidomide) [prescribing information]. Summit, NJ: Celgene Corporation;\u00a02013."},{"key":"10.1016\/j.clml.2015.05.007_bib45","unstructured":"Miguel J, Weisel K, Moreau P, et\u00a0al. Efficacy, safety, and QOL in MM-003, a phase 3, multicenter, randomized, open-label study of pomalidomide (POM)\u00a0+ low-dose dexamethasone (LoDEX) vs high-dose dexamethasone (HiDEX) in RRMM. Proceedings of the 18th Congress of the European Hematology Association (EHA), Stockholm, Sweden. Haematologica 2013; 98:475:abstract S1151."},{"key":"10.1016\/j.clml.2015.05.007_bib46","doi-asserted-by":"crossref","unstructured":"Song KW, Dimopoulos MA, Weisel KC, et al. Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. J Clin Oncol 2013; 31:abstract 8583.","DOI":"10.1200\/jco.2013.31.15_suppl.8583"},{"key":"10.1016\/j.clml.2015.05.007_bib47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/leu.2010.62","article-title":"Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease","volume":"24","author":"Terpos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.05.007_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2887.x","article-title":"Serum calcium is an independent predictor of quality of life in multiple myeloma","volume":"78","author":"Wisloff","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0609.2008.01126.x","article-title":"Psychosocial QOL is an independent predictor of\u00a0overall survival in newly diagnosed patients with multiple myeloma","volume":"81","author":"Strasser-Weippl","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2015.05.007_bib50","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2011-04-348896","article-title":"Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.05.007_bib51","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.05.007_bib52","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/leu.2010.190","article-title":"Pomalidomide (CC4047) plus low dose dexamethasone (Pom\/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)","volume":"24","author":"Lacy","year":"2010","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015003638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015003638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T11:28:24Z","timestamp":1717932504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015003638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S2152265015003638"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.05.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed\/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}